Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerResearch Summary
Analyzed using Evidence Intelligence™
Semaglutide improves glycemic control more than insulin aspart in type 2 diabetes
Last updated July 5, 2026
Key finding
HbA1c decreased by 1.5% points (16.6 mmol/mol).
This study compared once-weekly semaglutide to thrice-daily insulin aspart in adults with type 2 diabetes, revealing significant differences in HbA1c and body weight outcomes.
Quick read
Study at a glance
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Long-Term (1–5 y)
Risk of bias
Some Concerns
Save research, organize studies, and quickly find important evidence again.
Plain-language summary
What this paper says
A plain-language read of the study’s main message and where it applies.
Study focus
This study compared once-weekly semaglutide to thrice-daily insulin aspart in adults with type 2 diabetes, revealing significant differences in HbA1c and body weight outcomes.
Clinical relevance
These findings are significant as they suggest that once-weekly semaglutide may offer a more effective treatment option for adults with type 2 diabetes, leading to better management of blood sugar levels and weight loss. This could improve patient adherence to treatment and overall health outcomes, reducing the risk of diabetes-related complications.
Keep in mind
The study did not report on long-term effects beyond the trial duration. Sample size and demographic diversity may limit generalizability. The study did not explore patient adherence to medication.
Published in
Journal Reference
Publication details and source links for this paper.
Monika K, Margit SK, Jack L, et al. Once-Weekly Semaglutide versus Thrice-Daily Insulin Aspart in Adults with Type 2 Diabetes: A Randomized Trial. Diabetes, Obesity & Metabolism. 2022;24(9):1788-1799. doi:10.1111/dom.14765
Main Effects
HbA1c decreased by 1.5% points (16.6 mmol/mol) with semaglutide, p-value 0.0001.
HbA1c decreased by 1.2% points (13.4 mmol/mol) with insulin aspart, p-value 0.0001.
Body weight decreased by 4.1 kg with semaglutide.
Body weight increased by 2.8 kg with insulin aspart.
Evidence network
How this study fits
Understand where this research contributes within the broader evidence network.
Evidence Context
This study contributes evidence to Insulin aspart, Semaglutide and Body weight, HbA1c, Severe hypoglycemia.
This study contributes evidence to
Primary intervention
Insulin aspart
Primary outcomes
- Body weight
- HbA1c
- Severe hypoglycemia
Evidence topics
Primary intervention
Primary outcomes
Evidence relationships
Intervention and outcome relationships this study adds to the evidence network.
6
Evidence pairs
6
Relationships
3
Evidence topics
contributes_evidence
Editorial context
Why this study matters
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
Moderate contributionModerate confidenceNetwork score: 68
3
Related topics
6
Evidence pairs
730
Related studies
High relevance in at least one topic
Why it is useful
- Contributes to 6 evidence relationships
- Includes primary outcome data
- Linked to 3 direct semantic evidence topics
Topic contributions
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Add related evidence to your Evidence Tracker
Save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.
Primary evidence
Evidence relationship
GLP-1 Receptor Agonists and HbA1c
Related evidence
Evidence relationship
GLP-1 Receptor Agonists and Body Weight
Save evidence
Evidence relationship
GLP-1 Receptor Agonists and Hypoglycemia
Save evidence
Core evidence
Study findings
The primary outcomes reported in this study.
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- 85
- Strong
- ImpactScore™
- 72
- Positive
- ConsistencyScore™
- 88
- consistent
Supporting studies: Based on 9 studies
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- 86
- Strong
- ImpactScore™
- 91
- Very Positive
- ConsistencyScore™
- 82
- consistent
Supporting studies: Based on 11 studies
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Moderate
- Score 69 · Based on 2 studies
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- 100
- consistent
Supporting studies: Based on 2 studies
Add to Evidence TrackerEvidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Evidence Suggest
- Semaglutide reduced HbA1c by 1.5% points, significantly more than insulin aspart.
- Participants on semaglutide lost an average of 4.1 kg, while those on insulin gained weight.
- Both treatments had similar rates of severe hypoglycaemic episodes.
Who this applies to
- Adults diagnosed with type 2 diabetes.
- Patients requiring pharmacological management of blood sugar levels.
Keep in Mind
- Results may not apply to populations outside the study's demographic.
- The trial duration may not reflect long-term treatment outcomes.
- Further studies are needed to assess adherence and real-world effectiveness.
Between the Lines
- The study did not report on long-term effects beyond the trial duration.
- Sample size and demographic diversity may limit generalizability.
- The study did not explore patient adherence to medication.
Evidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Connected Evidence
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on GLP-1 Receptor Agonists and HbA1c, GLP-1 Receptor Agonists and Body Weight.
Related evidence relationships
Explore in Evidence ExplorerThis study contributes to the evidence on the following intervention-outcome relationships.
Medications
GLP-1 Receptor Agonists → HbA1c
Medications
Evidence Intelligence™
- EvidenceScore™
- 86
- Strong
- ImpactScore™
- 91
- Very Positive
- ConsistencyScore™
- 82
- consistent
Supporting studies: Based on 11 studies
View evidenceMedications
GLP-1 Receptor Agonists → Body Weight
Medications
Evidence Intelligence™
- EvidenceScore™
- 85
- Strong
- ImpactScore™
- 72
- Positive
- ConsistencyScore™
- 88
- consistent
Supporting studies: Based on 9 studies
View evidenceIncluded in these evidence collections
Curated evidence collections and hubs this study is part of.
GLP-1 Receptor Agonists Evidence Hub
All studies on GLP-1 Receptor Agonists
11 studies
intervention_hubContributes to GLP-1 Receptor Agonists evidence base.
HbA1c Evidence Hub
All studies measuring HbA1c
11 studies
outcome_hubMeasures HbA1c as a key outcome.
Body Weight Evidence Hub
All studies measuring Body Weight
9 studies
outcome_hubMeasures Body Weight as a key outcome.
Explore more in Evidence Explorer
Jump to pre-filtered views in Evidence Explorer.
All studies on Semaglutide and HbA1c
Intervention: SemaglutideOutcome: HbA1c
11 results
All studies on Semaglutide and Body weight
Intervention: SemaglutideOutcome: Body weight
9 results
All studies on Semaglutide
Intervention: Semaglutide
11 results
All studies measuring HbA1c
Outcome: HbA1c
11 results
All studies measuring Body weight
Outcome: Body weight
9 results
Questions answered by this study
Generated from the study's connected evidence using Evidence Intelligence™.
Does GLP-1 Receptor Agonists improve HbA1c?
Strong Evidence
GLP-1 Receptor Agonists appears to improve HbA1c.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
HbA1c
EvidenceScore™ Strong | EvidenceScore™ 85.5 | strong positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 32 supporting studies with consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does GLP-1 Receptor Agonists affect body weight?
Strong Evidence
GLP-1 Receptor Agonists may improve Body Weight.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
Body weight
EvidenceScore™ Strong | EvidenceScore™ 85.5 | moderate positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 33 supporting studies with consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does GLP-1 Receptor Agonists affect hypoglycemia?
Strong Evidence
GLP-1 Receptor Agonists may improve Hypoglycemia.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
Severe hypoglycemia
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | neutral | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 12 supporting studies with consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does Insulin aspart improve HbA1c?
Emerging Evidence
Insulin aspart appears to improve HbA1c.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
HbA1c
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Next steps
Continue your research
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Evidence topics
Follow the topics this study contributes to.
Explore in Evidence Explorer
Open broader Evidence Explorer views for this relationship.
Related research
Read related research summaries.
Semaglutide may reduce cardiovascular events in non-diabetic patients.Oral semaglutide reduces cardiovascular events in type 2 diabetesHigher semaglutide doses improve glucose control in type 2 diabetesNovel Semaglutide Injection Shows Non-Inferior Glycemic ControlOral semaglutide may improve cardiovascular event prevention in type 2 diabetes.
No ads. No tracking.
Focused on evidence, not advertising.
Secure & private
Your data is always protected.
Always up to date
New studies added every day.